

treatment for more aggressive cancers versus non aggressive treatment.

**Competitive Advantages:** The PCR based method is more advantageous and more objective than currently available histological classification and staging systems.

**Development Stage:**

- Early-stage.
- In vitro data available.
- In vivo data available (human).

**Inventors:** Guiseppe Giaccone and Yisong Wang (NCI).

**Publication:** Petrini I, et al. A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. *Nat Genet.* 2014 Aug;46(8):844–9. [PMID 24974848].

**Intellectual Property:** HHS Reference No. E–109–2014/0—US Provisional Application No. 61/975,222 filed April 4, 2014.

**Licensing Contact:** Sabarni Chatterjee, Ph.D., MBA; 301–435–5587; [chatterjeesa@mail.nih.gov](mailto:chatterjeesa@mail.nih.gov).

**Collaborative Research Opportunity:** For collaboration opportunities, please contact Dr. Guiseppe Giaccone at [gg496@georgetown.edu](mailto:gg496@georgetown.edu).

### Systems and Devices for Training and Imaging an Awake Test Animal

**Description of Technology:** The invention pertains to an apparatus and training system for rodents to maintain its head substantially motionless during an imaging procedure. The system includes a frame defining an enclosure for enclosing an animal therein during the imaging procedure which has a head post attached to the head of the animal and a treadmill having a plurality of rollers that the animal walks on such that one or more of the plurality of wheels rotate when the animal is in walking motion and stop rotating when the animal is in a substantially motionless state. This arrangement trains the animal to remain substantially motionless when disposed within an imaging apparatus. This invention permits prolonged imaging of awake rodents with minimal confinement and reduces stress.

**Potential Commercial Applications:**

- Imaging test rodents.
- Imaging pharmacological agent distribution in rodents.
- Imaging the therapeutically effects of pharmacological agent.

**Competitive Advantages:** Imaging while animal is awake.

**Development Stage:**

- Early-stage.
- Prototype.

**Inventors:** Hanbing Lu, Yihong Yang, Elliot Stein (all of NIDA).

**Intellectual Property:** HHS Reference No. E–043–2015/0—US Patent

Application 14/589,725 filed January 5, 2015.

**Licensing Contact:** Michael Shmilovich; 301–435–5019; [shmilovm@mail.nih.gov](mailto:shmilovm@mail.nih.gov).

**Collaborative Research Opportunity:** The National Institute on Drug Abuse is seeking statements of capability or interest from parties interested in collaborative research to further develop apparatus and/or the training system; commercialize with pharmaceutical industry. For collaboration opportunities, please contact Vio Conley, M.S. at [conleyv@mail.nih.gov](mailto:conleyv@mail.nih.gov).

### Miniature System for Manipulating Small Animals in High-Throughput Screening Small Molecules

**Description of Technology:** The invention pertains to a miniaturized plating and feeding system based on a 96-well microplate base and is intended to reduce manipulation of organisms as well as amounts of test drug/anesthetic, thereby mitigating waste. The kit comprises a feeder plate, transfer adaptor and receiver plate. The feeder plate is defined by, for example, a plastic 96-well plate with rounded wells. The rounded bottoms can dispense to or permit access to the test organism of liquid food or drug through about 7 holes of approximately 350 microns in diameter. A top portion of the well provides test organisms (*e.g.*, drosophila, daphnia) with sufficient space to enjoy normal life-cycles without confinement stress. The feeder plate includes means for interfacing with complementary components of the transfer and receiver plates through receiving holes and complementary dowels or pins. A transfer adapter allows the interconnection of the feeder plate to the receiver plate. The transfer plate can be configured to be square or rounded for the transfer of organisms from the feeder plate to the receiver plate.

**Potential Commercial Applications:**

- Drug Development.
- Toxicity Studies.
- Drug Design.

**Competitive Advantages:**

- Small animals.
- High Throughput.
- Space efficiency.
- Resource economy.

**Development Stage:**

- Early stage.
- Prototype.

**Inventors:** Maria De Los Angeles Jaime and Brian Oliver (NIDDK).

**Intellectual Property:** HHS Reference No. E–034–2015/0—US Provisional Application No. 62/080,181 filed November 14, 2014.

**Licensing Contact:** Michael Shmilovich, Esq.; 301–435–5019; [shmilovm@mail.nih.gov](mailto:shmilovm@mail.nih.gov).

**Collaborative Research Opportunity:** The National Institute of Diabetes and Digestive and Kidney Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize High-Throughput Small Animal Manipulation for Drug Design. For collaboration opportunities, please contact Marguerite J. Miller at [miller marg@nidDK.nih.gov](mailto:miller marg@nidDK.nih.gov).

This abstract replaces one published on Thursday, January 29, 2015 (80 FR 4935) to correct the patent application filing date.

Dated: March 12, 2015.

**Richard U. Rodriguez, M.B.A.,**

*Acting Director, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 2015–06123 Filed 3–17–15; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** Center for Scientific Review Special Emphasis Panel; PAR Panel: Cancer Health Disparities/Diversity in Basic Cancer Research.

**Date:** April 13–14, 2015.

**Time:** 8:00 a.m. to 5:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road, NW., Washington, DC 20015.

**Contact Person:** Nywana Sizemore, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6204, MSC 7804, Bethesda, MD 20892, 301–435–1718, [sizemoren@csr.nih.gov](mailto:sizemoren@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Program Project: National Biomedical NMR Resource.  
*Date:* April 13–15, 2015.  
*Time:* 7:00 p.m. to 12:00 p.m.  
*Agenda:* To review and evaluate grant applications.

*Place:* Doubletree Hotel Bethesda, (Formerly Holiday Inn Select), 8120 Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* Michael Eissenstat, Ph.D., Scientific Review Officer, BCMB IRG, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4166, Bethesda, MD 20892, 301–435–1722, [eissenstatma@csr.nih.gov](mailto:eissenstatma@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Member Conflict: AIDS and AIDS Related Research.

*Date:* April 13, 2015.

*Time:* 12:00 p.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Eduardo A Montalvo, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5108, MSC 7852, Bethesda, MD 20892, (301) 435–1168, [montalve@csr.nih.gov](mailto:montalve@csr.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: March 12, 2015.

**Carolyn A. Baum,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2015–06121 Filed 3–17–15; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; PAR–14–

085; Metabolic Reprogramming in Immunotherapy.

*Date:* March 17, 2015.

*Time:* 1:30 p.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Denise R Shaw, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6158, MSC 7804, Bethesda, MD 20892, 301–435–0198, [shawdeni@csr.nih.gov](mailto:shawdeni@csr.nih.gov).

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: March 12, 2015.

**Carolyn A. Baum,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2015–06120 Filed 3–17–15; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

[30Day–15–0020]

#### Agency Forms Undergoing Paperwork Reduction Act Review

The Centers for Disease Control and Prevention (CDC) has submitted the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The notice for the proposed information collection is published to obtain comments from the public and affected agencies.

Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address any of the following: (a) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (b) Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (c) Enhance the quality, utility, and clarity of the information to be collected; (d) Minimize the burden of

the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses; and (e) Assess information collection costs.

To request additional information on the proposed project or to obtain a copy of the information collection plan and instruments, call (404) 639–7570 or send an email to [omb@cdc.gov](mailto:omb@cdc.gov). Written comments and/or suggestions regarding the items contained in this notice should be directed to the Attention: CDC Desk Officer, Office of Management and Budget, Washington, DC 20503 or by fax to (202) 395–5806. Written comments should be received within 30 days of this notice.

#### Proposed Project

Coal Workers' Health Surveillance Program (CWHSP)—(0920–0020)—Reinstatement with Change—National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention (CDC).

#### Background and Brief Description

NIOSH would like to submit an Information Collection Request (ICR) to revise the data collection instruments being utilized within the Coal Workers' Health Surveillance Program (CWHSP).

On May 1, 2014, the Mine Safety and Health Administration (MSHA) published final rule 30 CFR 70, 71, 72, 75, and 90. The new MSHA rule added surface coal miners, a respiratory health assessment, and spirometry testing for chronic obstructive pulmonary disease (COPD) to the previously mandated chest x-ray examination program. These additions are being referred to as the Expanded CWHSP (an additional component under the current CWHSP).

This request incorporates all components that now fall under the CWHSP. Those components include: Coal Workers' X-ray Surveillance Program (CWXP), B Reader Program, Enhanced Coal Workers' Health Surveillance Program (ECWHSP), Expanded Coal Workers' Health Surveillance Program, and National Coal Workers' Autopsy Study (NCWAS).

The CWHSP is a congressionally-mandated medical examination program for monitoring the health of coal miners. The Program was originally authorized under the 1969 Federal Coal Mine Health and Safety Act and is currently authorized under the 1977 Federal Mine Safety and Health Act and its subsequent amendments (the Act). The Act provides the regulatory authority for